Efficacy of Rebamipide Enemas in Active Distal Ulcerative Colitis and Proctitis: A Prospective Study Report
- 105 Downloads
Rebamipide has a broad spectrum of pharmacological actions that include suppression of neutrophil functions and stimulation of mucosal epithelial cell regeneration by increasing the expression of epithelial growth factor (EGF) and the EGF receptor. Sixteen patients with active ulcerative colitis (UC; mild in 1 patient, moderate in 11, and severe in 4) were recruited. Enemas containing 150 mg rebamipide per dosing were administered during the daytime after passage of stool, twice a day for 4 weeks. UC disease activity index (UC-DAI), endoscopic activity index (EAI), and Floren's grading (FG) of mucosal biopsy specimens were measured at entry and at 4 weeks. Five of 16 patients did not complete the study, and therefore, final efficacy assessment was done on 11 patients who completed the 4 weeks of treatment. Improvements were observed in UC-DAI (P= 0.0049), EAI (P= 0.0043), and FG (P= 0.0084). There was no serious rebamipide-related side effect in any of the 16 patients. In conclusion, rebamipide topical therapy appears to be effective for the treatment of mildly to moderately active distal UC. Further controlled studies are warranted for this promising drug.
KeyWordsdistal ulcerative colitis rebamipide topical therapy
Unable to display preview. Download preview PDF.
- 1.Allison MC, Dhillon AP, Lewis WG, Pounder RE (eds): Inflammatory Bowel Disease. London, Mosby, 1998, pp 15–95Google Scholar
- 6.Yamamoto T, Umegae S, Kitagawa T, Yasuda Y, Yamada Y, Takahashi D, Mukumoto M, Nishimura N, Yasue K, Matsijimoto K: Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther 20:783–792, 2004CrossRefPubMedGoogle Scholar
- 7.Treulove SC: Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium: a report on a controlled therapeutic trial. Br Med J 2:1072–1077, 1958Google Scholar
- 10.Bianchi Porro G, Ardizzone S, Petrillo M, Fasoli A, Molteni P, Imbesi V: Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: A randomized, double-blind study. Am J Gastroenterol 90:736–739, 1995Google Scholar
- 11.Hanauer SB (for the U.S. PENTASA Enema Study Group): Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of multicentered placebo-controlled trial. Inflamm Bowel Dis 4:79–83, 1998Google Scholar
- 21.Farup PG, Hinterleitner TA, Lukas M, Hebuterne X, Rachmilewitz D, Campieri M, Meier R, Keller R, Rathbone B, Oddsson E: Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 7:237–242, 2001PubMedGoogle Scholar
- 24.Matts SGF: The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med, New Ser XXX 120:393–407, 1961Google Scholar
- 34.Aihara M, Azuma A, Takizawa H, Tsuchimoto D, Funakoshi Y, Shindo Y, Ohmoto Y, Imagawa K, Kikuchi M, Mukaida N, Matsushima K: Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci 43 (Suppl 9):174S–180S, 1998PubMedGoogle Scholar